🚀 VC round data is live in beta, check it out!
- Public Comps
- ArcticZymes
ArcticZymes Valuation Multiples
Discover revenue and EBITDA valuation multiples for ArcticZymes and similar public comparables like 4basebio, Pacific Edge, Clover Corp, Darwin and more.
ArcticZymes Overview
About ArcticZymes
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.
Founded
1990
HQ

Employees
55
Website
Financials (LTM)
EV
$78M
ArcticZymes Financials
ArcticZymes reported last 12-month revenue of $13M and EBITDA of $2M.
In the same LTM period, ArcticZymes generated $12M in gross profit, $2M in EBITDA, and $1M in net income.
Revenue (LTM)
ArcticZymes P&L
In the most recent fiscal year, ArcticZymes reported revenue of $12M and EBITDA of $1M.
ArcticZymes expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $13M | XXX | $12M | XXX | XXX | XXX |
| Gross Profit | $12M | XXX | $12M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $2M | XXX | $1M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $1M | XXX | $1M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 9% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ArcticZymes Stock Performance
ArcticZymes has current market cap of $105M, and enterprise value of $78M.
Market Cap Evolution
ArcticZymes' stock price is $2.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $105M | -0.8% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArcticZymes Valuation Multiples
ArcticZymes trades at 6.0x EV/Revenue multiple, and 44.2x EV/EBITDA.
EV / Revenue (LTM)
ArcticZymes Financial Valuation Multiples
As of April 18, 2026, ArcticZymes has market cap of $105M and EV of $78M.
Equity research analysts estimate ArcticZymes' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ArcticZymes has a P/E ratio of 74.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | 44.2x | XXX | 60.7x | XXX | XXX | XXX |
| EV/EBIT | 99.9x | XXX | 253.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.3x | XXX | 6.7x | XXX | XXX | XXX |
| P/E | 74.0x | XXX | 98.4x | XXX | XXX | XXX |
| EV/FCF | 18.9x | XXX | 16.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ArcticZymes Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ArcticZymes Margins & Growth Rates
ArcticZymes' revenue in the last 12 month grew by 20%.
ArcticZymes' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
ArcticZymes' rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ArcticZymes' rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ArcticZymes Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 100% | XXX | 129% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ArcticZymes Public Comps
See public comps and valuation multiples for other Bioindustrials and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ArcticZymes | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Edge | XXX | XXX | XXX | XXX | XXX | XXX |
| Clover Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Darwin | XXX | XXX | XXX | XXX | XXX | XXX |
| SDI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ArcticZymes M&A Activity
ArcticZymes acquired XXX companies to date.
Last acquisition by ArcticZymes was on XXXXXXXX, XXXXX. ArcticZymes acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ArcticZymes
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArcticZymes Investment Activity
ArcticZymes invested in XXX companies to date.
ArcticZymes made its latest investment on XXXXXXXX, XXXXX. ArcticZymes invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ArcticZymes
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ArcticZymes
| When was ArcticZymes founded? | ArcticZymes was founded in 1990. |
| Where is ArcticZymes headquartered? | ArcticZymes is headquartered in Norway. |
| How many employees does ArcticZymes have? | As of today, ArcticZymes has over 55 employees. |
| Is ArcticZymes publicly listed? | Yes, ArcticZymes is a public company listed on Oslo Børs. |
| What is the stock symbol of ArcticZymes? | ArcticZymes trades under AZT ticker. |
| When did ArcticZymes go public? | ArcticZymes went public in 2005. |
| Who are competitors of ArcticZymes? | ArcticZymes main competitors are 4basebio, Pacific Edge, Clover Corp, Darwin. |
| What is the current market cap of ArcticZymes? | ArcticZymes' current market cap is $105M. |
| What is the current revenue of ArcticZymes? | ArcticZymes' last 12 months revenue is $13M. |
| What is the current revenue growth of ArcticZymes? | ArcticZymes revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of ArcticZymes? | Current revenue multiple of ArcticZymes is 6.0x. |
| Is ArcticZymes profitable? | Yes, ArcticZymes is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ArcticZymes? | ArcticZymes' last 12 months EBITDA is $2M. |
| What is ArcticZymes' EBITDA margin? | ArcticZymes' last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of ArcticZymes? | Current EBITDA multiple of ArcticZymes is 44.2x. |
| What is the current FCF of ArcticZymes? | ArcticZymes' last 12 months FCF is $4M. |
| What is ArcticZymes' FCF margin? | ArcticZymes' last 12 months FCF margin is 32%. |
| What is the current EV/FCF multiple of ArcticZymes? | Current FCF multiple of ArcticZymes is 18.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.